MannKind Corporation is a biotechnology company focused on the development and commercialization of innovative therapies for diabetes and other chronic conditions. The company is best known for its product Afrezza, an inhalable form of insulin designed to provide a fast-acting alternative to traditional insulin delivery methods. In addition to its flagship product, MannKind is dedicated to advancing its research pipeline, which includes novel therapeutic options aimed at enhancing patient outcomes and improving quality of life for individuals with metabolic disorders. Through its commitment to scientific innovation and patient-centric solutions, MannKind aims to address significant unmet medical needs in the healthcare landscape. Read More
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload.
Chief Executive Officer Michael Castagna said the approval
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private placement to certain institutional investors. The gross proceeds from the private placement financing are expected to be approximately $50 million. The closing of the financing is expected to occur on or about July 24, 2026, subject to the satisfaction of customary closing conditions.
WESTLAKE VILLAGE, Calif., and BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure (HF) or chronic kidney disease (CKD).
Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million.
Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index.
Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced it has been awarded a grant from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes (T1D) research and advocacy organization, through its Industry Discovery and Development Partnership (IDDP) program, to support the ongoing INHALE-1ST clinical study evaluating the initiation of Afrezza® (insulin human) Inhalation Powder shortly after a type 1 diabetes diagnosis in pediatric patients.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced new clinical and real‑world data related to Afrezza® (insulin human) Inhalation Powder and FUROSCIX® (furosemide injection) that will be presented at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place June 5-8, 2026, in New Orleans, Louisiana.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, today announced key clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrollment of the first patient in the global Phase 2 INFLO-2 study. These milestones mark the advancement of the nintedanib DPI program and support its progression into mid-stage clinical evaluation.
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into children and adolescents.
Chief Executive Officer Michael Castagna called the decision “a truly historic
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Afrezza® (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that new clinical and real‑world data related to Afrezza® (insulin human) Inhalation Powder along with analyses of FUROSCIX® (furosemide injection) in patients with co-morbidities will be presented at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place June 5-8, 2026, in New Orleans, Louisiana.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the first quarter of 2026, and provided a business update.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it has been developing a dry powder inhalation (DPI) formulation of ralinepag, known as ralinepag DPI (MNKD-1501), for United Therapeutics Corporation (Nasdaq: UTHR), under the companies’ expanded license and collaboration agreement announcement from August 2025.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that new clinical and real‑world data related to Afrezza® (insulin human) Inhalation Powder will be presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026), taking place March 11–14, 2026, in Barcelona, Spain.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.
